Ali Ridvan, Ozkalemkaş Fahir, Ozçelik Tülay, Ozkocaman Vildan, Ozan Ulkü, Kimya Yalçin, Köksal Nilgün, Gülten Tuna, Yakut Tahsin, Tunali Ahmet
Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey.
Leuk Res. 2005 Aug;29(8):971-3. doi: 10.1016/j.leukres.2005.01.009. Epub 2005 Feb 16.
Because of the teratogenicity data in rats, it is recommended that women treated with imatinib should be aware of the potential teratogenicity of imatinib and effective contraception should be used during imatinib therapy to prevent pregnancy. We describe successful pregnancy and delivery, without any congenital anomaly, in a patient with CML under treatment of imatinib. The fetus had been exposed to imatinib for 8 weeks. The patient remained off treatment during gestation and cytogenetic relapse of CML (5 months after discontinuation of imatinib therapy) developed at seventh month of gestation.
鉴于大鼠的致畸性数据，建议接受伊马替尼治疗的女性应意识到伊马替尼的潜在致畸性，并且在伊马替尼治疗期间应采取有效的避孕措施以防止怀孕。我们描述了一名接受伊马替尼治疗的慢性粒细胞白血病患者成功怀孕并分娩，且胎儿无任何先天性异常的情况。胎儿在孕期暴露于伊马替尼8周。该患者在妊娠期间停止治疗，在妊娠第七个月时出现了慢性粒细胞白血病的细胞遗传学复发（伊马替尼治疗停药5个月后）。
